This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Icahn School of Medicine at Mount Sinai, University of Kansas. Active years: 2020.
Company Filing History:
1 out of 536 
1 out of 572 
Years Active: 2020
Title: Wenzhen Xiao: Innovator in Kidney Fibrosis Treatment
Introduction
Wenzhen Xiao is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medical research, particularly in the treatment of kidney fibrosis. His innovative work has led to the development of compounds that target specific pathways involved in fibrotic diseases.
Latest Patents
Wenzhen Xiao holds a patent for "Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis." This patent discloses compounds that are selective inhibitors of Smad3 activation. The compounds have a specific structure where Z is an oxadiazole. These compounds are particularly useful in treating fibrotic diseases, especially renal fibrosis, and similar conditions associated with the dysregulation of the HIPK2/Smad3 signaling pathway. He has 1 patent to his name.
Career Highlights
Throughout his career, Wenzhen Xiao has worked at prestigious institutions, including the Icahn School of Medicine at Mount Sinai and the University of Kansas. His research has focused on understanding and developing treatments for complex diseases, showcasing his dedication to advancing medical science.
Collaborations
Wenzhen Xiao has collaborated with esteemed colleagues such as John Cijiang He and Bhaskar C Das. These partnerships have contributed to the depth and impact of his research in the field.
Conclusion
Wenzhen Xiao's innovative work in developing oxadiazole inhibitors represents a significant advancement in the treatment of kidney fibrosis. His contributions to medical research continue to pave the way for new therapeutic options in combating fibrotic diseases.